Select Publications

Cavo M et al. Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) vs thalidomide- dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Proc ASH 2007;Abstract 73.

Hulin C et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Proc ASH 2007;Abstract 75.

Orlowski RZ et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression. J Clin Oncol 2007;25(25):3892-901. Abstract

Rajkumar SV et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology
Group. Proc ASH 2007;Abstract 74.

Richardson P et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study. Proc ASH 2007;Abstract 2714.

San Miguel JF et al. MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Proc ASH 2007;Abstract 76.

 

 

 

 

 

 

 

 

 

 

 

Table of Contents

Top of Page

Home

EDITOR
Neil Love, MD

INTERVIEWS
Susan M O’Brien, MD
- Select publications

Robert Z Orlowski, MD, PhD
- Select publications

David P Steensma, MD
- Select publications

David G Maloney, MD, PhD
- Select publications

Hematologic Oncology Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office